Your browser doesn't support javascript.
loading
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement.
Yen, Li-Chen; Chen, Hsin-Wei; Ho, Chia-Lo; Lin, Chang-Chi; Lin, Yi-Ling; Yang, Qiao-Wen; Chiu, Kuo-Chou; Lien, Shu-Pei; Lin, Ren-Jye; Liao, Ching-Len.
Afiliación
  • Yen LC; Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Chen HW; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35, Keyan Road, Zhunan, Miaoli County, 35053, Taiwan.
  • Ho CL; Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
  • Lin CC; Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Lin YL; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Yang QW; Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Chiu KC; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Lien SP; Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Lin RJ; Department of Family Dentistry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
  • Liao CL; School of Dentistry, National Defense Medical Center, Taipei, Taiwan.
J Biomed Sci ; 30(1): 41, 2023 Jun 14.
Article en En | MEDLINE | ID: mdl-37316861
ABSTRACT

BACKGROUND:

Flavivirus causes many serious public health problems worldwide. However, licensed DENV vaccine has restrictions on its use, and there is currently no approved ZIKV vaccine. Development of a potent and safe flavivirus vaccine is urgently needed. As a previous study revealed the epitope, RCPTQGE, located on the bc loop in the E protein domain II of DENV, in this study, we rationally designed and synthesized a series of peptides based on the sequence of JEV epitope RCPTTGE and DENV/ZIKV epitope RCPTQGE.

METHODS:

Immune sera were generated by immunization with the peptides which were synthesized by using five copies of RCPTTGE or RCPTQGE and named as JEV-NTE and DV/ZV-NTE. Immunogenicity and neutralizing abilities of JEV-NTE or DV/ZV-NTE-immune sera against flavivirus were evaluated by ELISA and neutralization tests, respectively. Protective efficacy in vivo were determined by passive transfer the immune sera into JEV-infected ICR or DENV- and ZIKV-challenged AG129 mice. In vitro and in vivo ADE assays were used to examine whether JEV-NTE or DV/ZV-NTE-immune sera would induce ADE.

RESULTS:

Passive immunization with JEV-NTE-immunized sera or DV/ZV-NTE-immunized sera could increase the survival rate or prolong the survival time in JEV-challenged ICR mice and reduce the viremia levels significantly in DENV- or ZIKV-infected AG129 mice. Furthermore, neither JEV -NTE- nor DV/ZV-NTE-immune sera induced antibody-dependent enhancement (ADE) as compared with the control mAb 4G2 both in vitro and in vivo.

CONCLUSIONS:

We showed for the first time that novel bc loop epitope RCPTQGE located on the amino acids 73 to 79 of DENV/ZIKV E protein could elicit cross-neutralizing antibodies and reduced the viremia level in DENV- and ZIKV-challenged AG129 mice. Our results highlighted that the bc loop epitope could be a promising target for flavivirus vaccine development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Zika / Infección por el Virus Zika Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Biomed Sci Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Zika / Infección por el Virus Zika Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Biomed Sci Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Taiwán